ClinicalTrials.gg
Not yet recruitingNCT07944677MACH3Updated Nov 18, 2026

Metabolism And Diet for Improving Kidney Cancer Health (MACH3)

An interventional study of Health Coaching and Time-Restricted Eating in Renal Cell Carcinoma, sponsored by University of Miami. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Miami · Not applicable, Interventional, and Supportive care

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to test whether a Mediterranean-style diet and a time-restricted eating plan ("intermittent fasting") are easy to follow and acceptable for people who were recently diagnosed with kidney cancer.

02

Conditions studied

  • Renal Cell Carcinoma
03

In context

Carcinoma, Renal Cell

2,041 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

This study's planned enrollment of 30 is below the median of 43 across 1,567 interventional studies indexed under Carcinoma, Renal Cell.

Browse Carcinoma, Renal Cell studies →

Lead sponsor

University of Miami is the lead sponsor of 843 studies on the registry; 167 are open to participants now.

Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Speak and understand English or Spanish
  • New diagnosis of clear cell renal cell carcinoma (RCC) who will undergo treatment with immunotherapy or immunotherapy-based combination treatments in the following two settings at the discretion of the treating investigator:
  • Post-operative adjuvant
  • setting

Immunotherapy treatments may include:

  • Pembrolizumab (adjuvant)
  • Ipilimumab/nivolumab (metastatic)
  • Pembrolizumab/Lenvatinib (metastatic)
  • Pembrolizumab/axitinib (metastatic)
  • Nivolumab/carbozantinib (metastatic)
  • Approval from medical oncologist to participate
  • No medical to immunotherapy or TKI therapy based on the treating physician's judgement

Exclusion criteria

Exclusion Criteria:

  • Already consistently following Mediterranean or time-restricted eating ("intermittent fasting") eating pattern in the past 3 months

    1. Not equal to or more than 50% of the time) engaged in structured fasting (i.e., not regularly fasting for ≥12hr/night)
    2. Not equal to or more than 50% of the time consuming >5 servings of fruits/vegetables per day, 2 servings of fatty fish per week, 3 servings nuts/seeds per week, and using olive oil as the primary dietary oil/fat
  • Insulin-dependent diabetes or current use of glipizide
  • Uncontrolled medical conditions (including dialysis, hypertension, cardiac disease)
  • Oxygen dependence
  • (ECOG) Performance status >3
  • \<12 months
  • Estimated (EGFR) \<40 mLs/min
  • History of disorders, or to immunotherapy
  • Active, untreated (brain mets)
  • Psychiatric history of mental state which would negatively impact participation and adherence to the intervention, e.g. major psychiatric disease, clinical eating disorder
  • \<20 kg/m2
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Arm 1: Intervention (MED+FAST)

    All intervention participants will receive the MED+FAST intervention, which combines time-restricted eating and a Mediterranean diet.

    Other: Health Coaching · Other: Time-Restricted Eating · Dietary Supplement: Mediterranean Diet · Other: Supportive Materials

  • No intervention
    Arm 2: Waitlist Control with Usual Care

    Participants randomized to the usual care arm will receive standard care with remote digital biomarker monitoring. Control participants will have the option to meet with the study health coach at the end of the 12-week study and will be directed to cancer survivorship services offered at Sylvester for additional support if requested.

Interventions

  • OtherHealth Coaching

    All participants will receive weekly health coaching sessions during the intervention via telephone, video call, or in-person, as feasible. The health coach will contact the participant after randomization to begin the intervention, which will include education on intermittent fasting and following a Mediterranean diet. Sessions are expected to last approximately 30-45 minutes and can be divided per participant preference.

  • OtherTime-Restricted Eating

    The intervention is designed to support participants in adopting timerestricted eating as part of their daily dietary routine. This approach is intended to modify the timing of food intake rather than reduce overall caloric intake, with participants encouraged to maintain their usual caloric intake within the prescribed eating window. Participants will be instructed to not consume any calorie-containing food/drinks after 8pm, or when their fasting window is scheduled per patient preference, and to wait 12-14 hours after the fasting start before resuming eating the next day.

  • Dietary supplementMediterranean Diet

    The intervention also aims to support participants in adopting key components of the Mediterranean diet alongside their time-restricted eating goals. In addition to meeting time-restricted eating goals, weekly coaching sessions will encourage participants to adopt key components of a Mediterranean diet.

  • OtherSupportive Materials

    To enhance adherence and engagement, participants in the intervention arm will receive multiple forms of support to help them successfully implement time-restricted eating and Mediterranean diet goals

06

What researchers measure

Primary outcomes

  1. Feasibility of Recruitment: Percentage of Participants That Consent to Participate and Meet Eligibility Criteria

    Feasibility of recruitment will reported as the percentage of participants who agree to participate (≥50%) at baseline.

    Time frame: Baseline

  2. Feasibility of Retention and Adherence: Percentage of Participants Who Adhere to and Complete the Intervention and Data Collection at All Time Points.

    Feasibility of retention and adherence will be reported as the percentage of intervention sessions completed (≥70%) at 12 weeks as measured by documented attendance/engagement each week with coach.

    Time frame: Up to 12 weeks

  3. Acceptability: Percentage of Participants Who Report Satisfaction with the Intervention

    Acceptability will be reported as the percentage of participants in the intervention arm of the study who report satisfaction with intervention (≥80%) at 12 weeks post-intervention as measured by 21-item participant satisfaction questionnaire, scores range from 0-5 with higher scores indicating greater satisfaction.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Overall Response Rate (ORR)

    Overall Response Rate (ORR) is the proportion of patients achieving complete response (CR) or partial response (PR) as the best response. ORR will be calculated as the proportion of participants achieving a complete or partial response at 12 weeks.

    Time frame: Up to 12 weeks

  2. Number of Participants Experiencing Adverse Events (AEs)

    Adverse events will be assessed using patient-reported and clinician-reported measures. The number of participants experiencing adverse events will be measured.

    Time frame: Up to 12 weeks

  3. Change in Physical Function (Handgrip Strength)

    Change in physical function (handgrip strength) will be assessed using a hand dynamometer. Percentage change in handgrip strength will be reported at baseline, 6 weeks, and 12 weeks by study arm.

    Time frame: Baseline, up to 12 weeks

  4. Change in Diet As Assessed by the Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)

    Patient-reported outcomes for change in diet (ASA24) will be evaluated using the Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool. This assessment will generate a score derived from the Healthy Eating Index (HEI). HEI scores range from 0 to 100, where higher numbers reflect better overall diet quality.

    Time frame: Baseline, up to 12 weeks

  5. Change in Physical Activity As Measured By Scores on the Godin Leisure Time Exercise Questionnaire

    Change in participant quality of life in both the intervention and control groups as measured by the Godin Leisure Time Exercise Questionnaire will be reported. The Godin Leisure Time Exercise Questionnaire assesses participants' frequency of leisure activity/exercise (strenuous, moderate or light) for more than 15 minutes during a 7-day period. Higher scores (≥24) indicate a more active lifestyle and lower scores (≤23) indicate an insufficiently active lifestyle. Scores collected at baseline (T1) will be compared to scores collected 6 weeks (T2) and week 12 (T3).

    Time frame: Baseline, up to 12 weeks

  6. Change in Quality of Life As Measured By Scores on the PROMIS-29 Questionnaire

    Change in participant quality of life in both the intervention and control groups as measured by scores on the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) questionnaire will be reported. PROMIS-29 questionnaire is a 29-item validated measure using a single 0-10 numeric rating item with seven domains of health, including physical function, anxiety, depression, pain interference, fatigue, sleep disturbance, ability to participate in social roles and activities and pain intensity. Scores collected at baseline (T1) will be compared to scores collected at 6 weeks (T2) and 12 weeks (T3). Higher scores represent worse symptoms for symptom-oriented domains (anxiety, depression, fatigue, pain intensity, pain interference, and sleep disturbance) and better health outcomes for function-oriented domains (physical functioning and ability to participate in social roles and activities).

    Time frame: Baseline, up to 12 weeks

  7. Change in Sleep Quality as Assessed by the Pittsburgh Sleep Quality Index

    Patient-reported outcomes for change in sleep will be evaluated using the Pittsburgh Sleep Quality Index. The Pittsburgh Sleep Quality Index (PSQI) is a 19-item questionnaire used to measure the quality and patterns of sleep in adults. It evaluates sleep across seven component scores, which are summed to create a single global score ranging from 0 to 21 (where higher scores indicate poorer sleep quality).

    Time frame: Baseline, up to 12 weeks

  8. Change in Physical Activity as Measured By Participant Accelerometry Data, in Steps Per Day

    Participant physical activity will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3). Physical activity measures will include average daily step count in steps per day.

    Time frame: Baseline, 12 weeks

  9. Change in Physical Activity as Measured By Participant Accelerometry Data, in Minutes Per Day

    Participant physical activity will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3). Physical activity measures will include sedentary time; light-intensity physical activity (LPA); moderate-intensity physical activity (MPA); vigorous-intensity physical activity (VPA); and total physical activity all in minutes per day.

    Time frame: Baseline, 12 weeks

  10. Change in Sleep as Measured By Participant Accelerometry Data, in Minutes Per Night

    Participant sleep will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3). Sleep measures will include total sleep time; wake after sleep onset (WASO); and time in bed by minutes per night.

    Time frame: Baseline, 12 weeks

  11. Change in Sleep as Measured By Participant Percentage of Sleep Efficiency

    Participant sleep will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3). Sleep measures will include percentage of sleep efficiency.

    Time frame: Baseline, 12 weeks

  12. Change in Sleep as Measured By Participant Accelerometry Data, in Awakenings Per Night

    Participant sleep will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3). Sleep measures will include number of awakenings in awakenings per night.

    Time frame: Baseline, 12 weeks

  13. Change in Sleep as Measured By Participant Accelerometry Data, in Minutes

    Participant sleep will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3). Sleep measures will include sleep onset latency in minutes.

    Time frame: Baseline, 12 weeks

  14. Change in Anthropometrics

    Changes in anthropometric measurements will be assessed using standard-of-care abdominal CT and MRI scans. Anthropometric measures will include height in centimeters (cm); body weight in kilograms (kg); body mass index (BMI) in kilograms per meter squared (kg/m\^2); waist circumference in cm; hip circumference in cm; waist-to-hip ratio (if calculated).

    Time frame: Baseline, 12 weeks

  15. Change in Body Composition

    Changes in body composition characteristics will be assessed using standard-of-care abdominal CT and MRI scans. Omron BIA measures will include percentage of total body fat; percentage of skeletal muscle; and visceral fat rating (unitless). CT-derived composition measures will include skeletal muscle cross-sectional area in cm\^2; skeletal muscle index (SMI) in cm\^2/m\^2; visceral adipose tissue are (VAT) in cm\^2; subcutaneous adipose tissue are (SAT) in cm\^2; skeletal muscle radiodensity in Hounsfield units (HU); and intramuscular adipose tissue area in cm\^2.

    Time frame: Baseline, 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2030, 48 months later.

Of 120 non-industry interventional studies with no phase under Carcinoma, Renal Cell, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 114. This study's planned 48 months is close to that.

Counting every sponsor, half of 127 studies reached it within 45 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2026
First posted
Nov 18, 2026
StartEst.
Dec 21, 2026
Primary completionEst.
Dec 21, 2030
CompletionEst.
Dec 21, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944677
Responsible party
Tracy E Crane, PhD, RDN (Associate Professor, University of Miami) — Principal investigator
First posted
Nov 18, 2026
Start date
Dec 21, 2026 (estimated)
Primary completion
Dec 21, 2030 (estimated)
Completion
Dec 21, 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Tracy Crane, PhD
Contact
tecrane@miami.edu
(305) 243-8255
Jamie Merchan, MD
Contact
jmerchan2@med.miami.edu
(305) 243-1287
Tracy Crane, PhD
principal investigator · University of Miami

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion